The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Exploring Environmental and Genetic Mediators of Progression in Parkinson’s Disease
Study Rationale:
We currently do not understand why some people with Parkinson’s disease (PD) have particularly severe symptoms, or symptoms that progress rapidly, compared to those who do not. This... -
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Targeting a Phospholipid Unique to Mitochondrial Membranes as a Therapeutic for Parkinson’s Disease
Study Rationale: Mitochondria are energy-generating structures vital to the health of all cells. In Parkinson’s disease (PD), mitochondrial dysfunction leads to neuronal degeneration and to the motor...
-
Rapid Response Innovation Awards, 2011Informing Clinical Decision Making in the Pre-motor Period of Parkinson Disease
Objective/Rationale:
Currently, the diagnosis of Parkinson disease (PD) relies on recognition of impaired movement, which occurs decades after neurodegeneration begins. By looking at changes in sleep... -
Research Grant, 2018Searching Brain Scan Data for Patterns of Activity Associated with Parkinson's Disease
Study Rationale:
There is a pressing need for Parkinson's disease (PD) biomarkers -- objective measures of disease -- that will enable early and accurate diagnosis and allow to track disease... -
Rapid Response Innovation Awards, 2011Alpha-synuclein and Tau Mislocalization to Dendritic Spines
Objective/Rationale:
In addition to motor disorders, Parkinson disease (PD) patients also suffer from cognitive deficits, which are believed to result from abnormal accumulation of alpha-synuclein, a... -
Parkinson’s Disease Therapeutics Pipeline Program, 2025Isoform Specific Suppression of dIRE-SNCA with an ASO
Study Rationale: Alpha-synuclein (SNCA) aggregation is a hallmark of Parkinson’s disease (PD). Rare SNCA genetic duplications and triplications cause early-onset PD, suggesting a link between SNCA...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.